Camizestrant
A selective estrogen receptor degrader
| Camizestrant | |
|---|---|
| |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Camizestrant is a selective estrogen receptor degrader (SERD) that is being investigated for the treatment of hormone receptor-positive breast cancer. It is designed to bind to the estrogen receptor and promote its degradation, thereby inhibiting the growth of cancer cells that rely on estrogen signaling.
Mechanism of Action[edit | edit source]
Camizestrant functions by targeting the estrogen receptor (ER) for degradation. Unlike traditional selective estrogen receptor modulators (SERMs), which block the receptor, SERDs like camizestrant lead to the receptor's destruction. This process reduces the number of receptors available for estrogen binding, effectively diminishing the estrogen-driven proliferation of cancer cells. This mechanism is particularly beneficial in breast cancer cases that have developed resistance to other forms of endocrine therapy.
Clinical Development[edit | edit source]
Camizestrant is currently undergoing clinical trials to evaluate its efficacy and safety in patients with advanced or metastatic hormone receptor-positive breast cancer. These trials aim to determine the optimal dosing regimen and to compare the effectiveness of camizestrant with existing therapies such as fulvestrant and aromatase inhibitors.
Potential Benefits[edit | edit source]
The development of camizestrant represents a significant advancement in the treatment of hormone receptor-positive breast cancer. By offering a novel mechanism of action, camizestrant has the potential to overcome resistance to current endocrine therapies. This could provide a new line of treatment for patients who have limited options due to the progression of their disease.
Side Effects[edit | edit source]
As with any therapeutic agent, camizestrant may have side effects. Commonly observed adverse effects in clinical trials include nausea, fatigue, and hot flashes. Ongoing studies continue to monitor the safety profile of camizestrant to ensure its benefits outweigh any potential risks.
Related pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
